-
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
- Marine Maurel1,* , Jennifer Howard1,* , Esther Kissling1 , Francisco Pozo2,3 , Gloria Pérez-Gimeno3,4 , Silke Buda5 , Noémie Sève6 , Adele McKenna7 , Adam Meijer8 , Ana Paula Rodrigues9 , Iván Martínez-Baz10 , Ivan Mlinarić11 , Neus Latorre-Margalef12 , Gergő Túri13 , Mihaela Lazăr14 , Clara Mazagatos3,4 , Aitziber Echeverria10 , Stephen Abela15 , Marc Bourgeois16 , Ausenda Machado9 , Ralf Dürrwald17 , Goranka Petrović11 , Beatrix Oroszi13 , Ligita Jancoriene18 , Alexandru Marin19 , Petr Husa20 , Roisin Duffy7 , Frederika Dijkstra8 , Virtudes Gallardo García21 , Luise Goerlitz5 , Vincent Enouf22 , Charlene Bennett23 , Mariëtte Hooiveld24 , Raquel Guiomar25 , Camino Trobajo-Sanmartín10 , Vesna Višekruna Vučina11 , Tove Samuelsson Hagey12 , Ana Sofía Lameiras Azevedo26 , Jesús Castilla10 , Gerd Xuereb15,27 , Bénédicte Delaere16 , Verónica Gómez9 , Kristin Tolksdorf5 , Sabrina Bacci28 , Nathalie Nicolay28 , Marlena Kaczmarek28 , Angela MC Rose1 , on behalf of the European IVE group29
-
View Affiliations Hide AffiliationsAffiliations: 1 Epiconcept, Paris, France 2 National Centre for Microbiology, National Influenza Reference Laboratory, WHO-National Influenza Centre, Institute of Health Carlos III, Madrid, Spain 3 CIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain 4 National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain 5 Department for Infectious Disease Epidemiology, Respiratory Infections Unit, Robert Koch Institute, Berlin, Germany 6 Sorbonne Université, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France 7 HSE Health Protection Surveillance Centre, Dublin, Ireland 8 National Institute for Public Health and the Environment, Centre for Infectious Diseases Control, Bilthoven, the Netherlands 9 Epidemiology Department, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal 10 Instituto de Salud Pública de Navarra – IdiSNA – CIBERESP, Pamplona, Spain 11 Croatian Institute of Public Health, Zagreb, Croatia 12 Public Health Agency of Sweden, Stockholm, Sweden 13 National Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary 14 Cantacuzino National Military Medical Institute for Research and Development, Bucharest, Romania 15 Infectious Disease Prevention and Control Unit (IDCU), Health Promotion and Disease Prevention, Msida, Malta 16 Department of Infectious Diseases, CHU UCL Namur (site Godinne), Université catholique de Louvain, Yvoir, Belgium 17 National Reference Centre for Influenza, Robert Koch Institute, Berlin, Germany 18 Clinic of Infectious Diseases and Dermatovenerology, Institute of Clinical Medicine, Medical Faculty, Vilnius University, Vilnius, Lithuania 19 Dr Victor Babes Clinical Hospital of Infectious and Tropical Diseases, Bucharest, Romania 20 University Hospital Brno and Masaryk University, Brno, Czechia 21 Servicio de Vigilancia y Salud Laboral, Dirección General de Salud Pública y Ordenación Farmacéutica, Consejería de Salud y Consumo, Andalucía, Spain 22 Centre National de Référence Virus des Infections Respiratoire (CNR VIR), Institut Pasteur Université Paris Cité, Paris, France 23 National Virus Reference Laboratory, University College Dublin, Dublin, Ireland 24 Nivel, Utrecht, the Netherlands 25 Laboratório Nacional Referência Gripe e outros Vírus Respiratórios, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal 26 Servicio de vigilancia y control epidemiológico, Subdirección general de Epidemiología y Vigilancia de la Salud, Dirección General de Salud pública, Valencia, Spain 27 Department of Child and Adolescent Health, Mater Dei Hospital, Msida, Malta 28 European Centre for Disease Prevention and Control, Stockholm, Sweden 29 The members of the European IVE group are listed under Acknowledgements.* These authors contributed equally to this article and share first authorship.Correspondence:Esther Kisslinge.kissling epiconcept.fr
-
View Citation Hide Citation
Citation style for this article: Maurel Marine, Howard Jennifer, Kissling Esther, Pozo Francisco, Pérez-Gimeno Gloria, Buda Silke, Sève Noémie, McKenna Adele, Meijer Adam, Rodrigues Ana Paula, Martínez-Baz Iván, Mlinarić Ivan, Latorre-Margalef Neus, Túri Gergő, Lazăr Mihaela, Mazagatos Clara, Echeverria Aitziber, Abela Stephen, Bourgeois Marc, Machado Ausenda, Dürrwald Ralf, Petrović Goranka, Oroszi Beatrix, Jancoriene Ligita, Marin Alexandru, Husa Petr, Duffy Roisin, Dijkstra Frederika, Gallardo García Virtudes, Goerlitz Luise, Enouf Vincent, Bennett Charlene, Hooiveld Mariëtte, Guiomar Raquel, Trobajo-Sanmartín Camino, Višekruna Vučina Vesna, Samuelsson Hagey Tove, Lameiras Azevedo Ana Sofía, Castilla Jesús, Xuereb Gerd, Delaere Bénédicte, Gómez Verónica, Tolksdorf Kristin, Bacci Sabrina, Nicolay Nathalie, Kaczmarek Marlena, Rose Angela MC, on behalf of the European IVE group. Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024. Euro Surveill. 2024;29(8):pii=2400089. https://doi.org/10.2807/1560-7917.ES.2024.29.8.2400089 Received: 12 Feb 2024; Accepted: 21 Feb 2024
- Previous Article
- Table of Contents
- Next Article
Abstract
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: −3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: −32 to 43), respectively.
Article metrics loading...
Full text loading...
References
-
European Centre for Disease Prevention and Control (ECDC). European Respiratory Virus Surveillance Summary (ERVISS), 2024, Week 05. Stockholm: ECDC. [Accessed: 16 Feb 2024]. Available from: https://erviss.org
-
World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2023-2024 northern hemisphere influenza season. Geneva: WHO; 2023. Available from: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2023-2024-northern-hemisphere-influenza-season
-
European Centre for Disease Prevention and Control (ECDC). Vaccine Scheduler. Stockholm: ECDC. [Accessed: 31 Jan 2024]. Available from: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=15&SelectedCountryIdByDisease=-1
-
European Centre for Disease Prevention and Control (ECDC). Core protocol for ECDC studies of vaccine effectiveness against symptomatic laboratory-confirmed influenza or SARS-CoV-2 infection at primary care level: version 1.0, September 2023. Stockholm: ECDC; 2023. Available from: https://data.europa.eu/doi/10.2900/25966
-
European Centre for Disease Prevention and Control (ECDC). Core protocol for ECDC VEBIS studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection laboratory-confirmed with SARS-CoV-2 or seasonal influenza - Version 2.0. Stockholm: ECDC; 2023. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-vaccine-effectiveness-sari-protocol-version-2.pdf
-
Covenay J. FIRTHLOGIT: Stata module to calculate bias reduction in logistic regression. Boston: Boston College Department of Economics; 2015. Available from: https://EconPapers.repec.org/RePEc:boc:bocode:s456948
-
European Centre for Disease Prevention and Control (ECDC). Influenza virus characterisation, Summary Europe, December 2023. Stockholm: ECDC; 2024. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/influenza-ECDC-WHO-Report-december-2023.pdf
-
European Centre for Disease Prevention and Control (ECDC). Influenza virus characterisation, Summary Europe, August 2023. Stockholm: ECDC; 2023. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/Influenza-characterization-August-2023.pdf
-
World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2022-2023 northern hemisphere influenza season. Geneva: WHO. [Accessed: 3 Feb 2023]. Available from: https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2022-2023-northern-hemisphere-influenza-season
-
Skowronski DM, Zhan Y, Kaweski SE, Sabaiduc S, Khalid A, Olsha R, et al. 2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN). Euro Surveill. 2024;29(7):2400076. https://doi.org/10.2807/1560-7917.ES.2024.29.7.2400076 PMID: 38362622
-
Maurel M, Pozo F, Pérez-Gimeno G, Buda S, Sève N, Oroszi B, et al. Influenza vaccine effectiveness in Europe: Results from the 2022-2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study. Influenza Other Respir Viruses. 2024;18(1):e13243. https://doi.org/10.1111/irv.13243 PMID: 38204584
-
Rose A, Pozo F, Martínez-Baz I, Mazagatos C, Bossuyt N, Cauchi JP, et al. Vaccine effectiveness against influenza hospitalisation in adults during the 2022/23 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network. Influenza Other Respir Viruses. 2024;18(2). https://doi.org/10.1111/irv.13255
-
Smolarchuk C, Ickert C, Zelyas N, Kwong JC, Buchan SA. Early influenza vaccine effectiveness estimates using routinely collected data, Alberta, Canada, 2023/24 season. Euro Surveill. 2024;29(2):2300709. https://doi.org/10.2807/1560-7917.ES.2024.29.2.2300709 PMID: 38214082
Data & Media loading...